and from my notes in this post, a total of 65.8% of Breast Cancer patients receive anthracycline-based chemotherapy (which is dangerous for the heart).
So if the chinese study is accurate (it is over 10 years old now), RACE are looking to replace Anthracyclines, so are aiming at a massively wide zone that covers 65.8% of the Breast Cancer chemotherapy market.
RAC Primer, page-103
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.83 |
Change
-0.030(1.61%) |
Mkt cap ! $311.7M | |||
| Open | High | Low | Value | Volume |
| $1.86 | $1.91 | $1.79 | $169.3K | 92.02K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 92 | $1.83 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.87 | 3472 | 1 |
View Market Depth
| Last trade - 16.10pm 19/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |